drugset
drugset / Trial / NCT02259842

Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers

NCT02259842 ↗

Phase 1 Completed 63 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluation of safety, tolerability and PK of single rising oral doses of BI 34021 FU2 in healthy male volunteers; comparison of 100 mg drinking solution vs. tablet, assessment of food effect by re-dosing at 50 mg and 150 mg

Timeline

Start
2008-03
Primary completion
2008-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 34021 FU2 Unknown 50 mg Oral
Subject BI 34021 FU2 Unknown 100 mg Oral
Subject BI 34021 FU2 Unknown 150 mg Oral

Indications

No indication recorded.